AMG 900 (AMG-900), a phtha-lazinamine compound, is a novel and ATP-competitive pan-Aurora (A/B/C) kinase inhibitor with potential antitumor activity.

PF-03814735 (PF03814735) is a reversible, orally bioavailable, and ATP-competitive inhibitor of Aurora A/B kinases with potential antitumor activity.

Tozasertib (formerly VX-680; MK-0457) is a novel and potent pan-Aurora kinase (AK) inhibitor with potential anticancer activity.

Danusertib (formerly PHA-739358), a pyrrolo-pyrazole compound, is a potent Aurora kinase inhibitor of Aurora A/B/C with potential antitumor activity.

Hesperadin is a novel, potent and ATP-competitive inhibitor of human aurora B kinase with potential antitumor activity.

BI-847325 (BI847325) is a novel, potent, orally bioavailable, and selective dual inhibitor of MEK (mitogen-activated protein kinase kinase) and Aurora kinase with potential antitumor activity.

CYC116 is a novel, potent, orally bioavailable inhibitor of Aurora A/B/C kinases with potential antitumor activity.

MLN-8054 (MLN8054), a benzazepine-based compound, is a selective, and ATP-competitive inhibitor of Aurora A kinase (AAK) with potential antitumor activity.

ZM 447439 (ZM-447439) is a novel, potent, selective and ATP-competitive inhibitor of Aurora A and Aurora B with potential antitumor activity.

MK-5108 (also known as VX-689) is a novel, specific and ATP-competitive inhibitor of Aurora A kinase with potential anticancer activity.